Avidity Partners Management LP United Therapeutics Corp Transaction History

Avidity Partners Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$228.26 - $319.04 $24.4 Million - $34.1 Million	-107,000 Reduced 49.31%	110,000 $35 Million
Q1 2024 May 15, 2024	SELL	$210.76 - $249.51 $4.26 Million - $5.04 Million	-20,202 Reduced 8.52%	217,000 $49.8 Million
Q4 2023 Feb 14, 2024	BUY	$214.88 - $256.94 $51 Million - $60.9 Million	237,202 New	237,202 $52.2 Million
Q4 2022 Feb 14, 2023	SELL	$205.95 - $280.43 $38 Million - $51.8 Million	-184,700 Reduced 19.04%	785,500 $218 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $49.7 Million - $59.7 Million	244,600 Added 33.71%	970,200 $203 Million
Q2 2022 Aug 15, 2022	BUY	$174.81 - $241.14 $1.16 Million - $1.6 Million	6,654 Added 0.93%	725,600 $171 Million
Q1 2022 May 16, 2022	BUY	$166.16 - $213.96 $30.6 Million - $39.4 Million	183,946 Added 34.38%	718,946 $129 Million
Q4 2021 Feb 14, 2022	BUY	$184.32 - $216.08 $33.9 Million - $39.8 Million	184,000 Added 52.42%	535,000 $116 Million
Q3 2021 Nov 15, 2021	BUY	$179.86 - $214.88 $20.6 Million - $24.6 Million	114,600 Added 48.48%	351,000 $64.8 Million
Q2 2021 Aug 16, 2021	BUY	$170.47 - $211.93 $40.3 Million - $50.1 Million	236,400 New	236,400 $42.4 Million

672

42.3M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.2B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.